OBJECTIVE: To investigate the dosage consistency of botulinum toxin injections in patients with long-term treatment for laryngeal dystonia.
STUDY DESIGN: Chart review.
SUBJECTS AND METHODS: Patients with laryngeal dystonia who had received at least 20 injections to the thyroarytenoid muscle were selected. Change of botulinum toxin dose, patient-reported effective weeks, and intervals between injections were investigated; data from the first five injections were excluded to eliminate initial dose titration.
RESULTS: Fifty-five patients with an average follow-up of 12.5 years were identified. Mean dose of botulinum toxin was 2.37 ± 1.6 U at the sixth injection; there was a decrease in mean dose over time, which became statistically significant at the 13th injection with a mean dose of 2.02 ± 1.16 U. Mean duration of good effect and treatment intervals showed no significant change over time.
CONCLUSION: Botulinum toxin dose needed for a constant response in treatment of laryngeal dystonia decreases over time, without any accompanying change in effective weeks and intervals.
Get full access to this article
View all access options for this article.
References
1.
BlitzerABrinMFFahnS. Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases.Laryngoscope1988;98:636–40
2.
HillelAD. The study of laryngeal muscle activity in normal human subjects and in patients with laryngeal dystonia using multiple fine-wire electromyography.Laryngoscope2001;111(4 pt 2 suppl 97):1–47
3.
BlitzerABrinMFFahnS. Botulinum toxin (BOTOX) for the treatment of “spastic dysphonia” as part of a trial of toxin injections for the treatment of other cranial dystonias.Laryngoscope1986;96:1300–1
4.
American Academy of Otolaryngology—Head and Neck Surgery.Policy statement: botulinum toxin.Alexandria (VA): American Academy of Otolaryngology—Head and Neck Surgery. Revised April 9, 1997; reaffirmed March 1998:1
5.
BlitzerASulicaL. Botulinum toxin: basic science and clinical uses in otolaryngology.Laryngoscope2001;111:218–26
6.
ChangCYChabotPThomasJP. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia.Otolaryngol Head Neck Surg2007;136:894–9
7.
HoldenPKVokesDETaylorMB. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia.Ann Otol Rhinol Laryngol2007;116:891–6
8.
BlitzerABrinMFStewartCF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.Laryngoscope1998;108:1435–41
9.
TischSHBrakeHMLawM. Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients—an Australian experience.J Clin Neurosci2003;10:434–8
10.
SmithMEFordCN. Resistance to botulinum toxin injections for spasmodic dysphonia.Arch Otolaryngol Head Neck Surg2000;126:533–5
11.
BorodicGEFerranteR. Effects of repeated botulinum toxin injections on orbicularis oculi muscle.J Clin Neuroophthalmol1992;12:121–7
12.
DavidsonBJLudlowCL. Long-term effects of botulinum toxin injections in spasmodic dysphonia.Ann Otol Rhinol Laryngol1996;105:33–42
13.
InagiKConnorNPSchultzE. Muscle fiber-type changes induced by botulinum toxin injection in the rat larynx.Otolaryngol Head Neck Surg1999;120:876–83
14.
WhiteCMGreensmithLVrbováG. Repeated stimuli for axonal growth causes motoneuron death in adult rats: the effect of botulinum toxin followed by partial denervation.Neuroscience2000;95:1101–9
15.
GiladiN. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site.J Neurol Sci1997;152:132–5
16.
AntonucciFRossiCGianfranceschiL. Long-distance retrograde effects of botulinum neurotoxin A.J Neurosci2008;28:3689–96
17.
GilioFCurràALorenzanoC. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia.Ann Neurol2000;48:20–6
18.
ByrnesMLThickbroomGWWilsonSA. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection.Brain1998;121:977–88
19.
BielamowiczSLudlowCL. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.Ann Otol Rhinol Laryngol2000;109:194–203
20.
CroesSABaryshnikovaLMKaluskarSS. Acute and long-term effects of botulinum neurotoxin on the function and structure of developing extraocular muscles.Neurobiol Dis2007;25:649–64
21.
BrashearAHoganPWooten-WattsM. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia.Adv Ther2005;22:49–55
22.
Echeverría UrabayenAFanjulSMeseguerE. Progression of botulinum toxin type A dosage in craniocervical dystonias. An eight year comparative study.Rev Neurol2004;38:511–3
